Sample Size Determination for Phase II Clinical Trials Based on Bayesian Decision Theory
From MaRDI portal
Publication:4665959
DOI10.2307/2534014zbMath1058.62656WikidataQ47291830 ScholiaQ47291830MaRDI QIDQ4665959
Publication date: 11 April 2005
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.2307/2534014
optimal stopping; cost-benefit analysis; backwards induction; multistage design; group sequential procedure
62P10: Applications of statistics to biology and medical sciences; meta analysis
62C10: Bayesian problems; characterization of Bayes procedures
62L05: Sequential statistical design
Related Items
Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes, Bayesian designs with frequentist and Bayesian error rate considerations, Bayesian approach to determine the number of subsequent users of a new treatment